Background. Left atrial enlargement is a mortality and heart failure risk factor in primary mitral regurgitation (MR) patients. Pig models of MR have shown differential expression of genes linked to the renin-angiotensin system. Therefore, the aim of this study was to investigate the key genes of the renin-angiotensin that are expressed differentially in the left atrial myocardium in MR patients. Methods. Quantitative RT-PCR was used to compare gene expression in the renin-angiotensin system in the left atrium in MR patients, aortic valve disease patients, and normal subjects. Results. Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (P = 0 582). Compared to normal controls, however, MR patients had significantly downregulated expressions of angiotensin-converting enzyme, angiotensin I converting enzyme 2, type 1 angiotensin II receptor, glutamyl aminopeptidase, angiotensinogen, cathepsin A (CTSA), thimet oligopeptidase 1, neurolysin, alanyl aminopeptidase, cathepsin G, leucyl/cystinyl aminopeptidase (LNPEP), neprilysin, and carboxypeptidase A3 in the left atrium. The MR patients also had significantly upregulated expressions of MAS1 oncogene (MAS1) and mineralocorticoid receptor compared to normal controls. Additionally, in comparison with aortic valve disease patients, MR patients had significantly downregulated CTSA and LNPEP expression and significantly upregulated MAS1 expression in the left atrium. Conclusions. Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from expressions of these genes in aortic valve disease patients and normal controls. Notably, differences in expression were independent of circulating angiotensin II levels. The results of this study provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting genes expressed differentially in the renin-angiotensin system to remedy structural remodeling associated with atrial enlargement and heart failure progression in patients with MR.
Introduction
Mitral regurgitation (MR) is the second most prevalent valvular heart disease after aortic valve stenosis [1] and a major cause of heart failure (HF). Even under medical treatment, annual mortality rates approximate 3% in patients with moderate primary MR and 6% in patients with severe primary MR [2] . Left atrial enlargement is also an important risk factor for mortality, HF, and cardiac events in primary MR patients under regular medical management [3] . Notably, atrial myocardial stretch with left atrial enlargement results from volume overload caused by an MR with a blood jet into the left atrium. In MR patients with HF, structural remodeling associated with atrial enlargement may also occur in the left atrial myocardium [4, 5] . A previous study in adult rats also revealed that myocyte stretching that mimics volume overload can induce angiotensin II synthesis and myocyte apoptosis, which could then be abolished by angiotensin II type I receptor blocker [6] . Interestingly, a pig model of MR in our previous study revealed differential expression of genes related to structural remodeling of the left atrium [7] . Analyses of gene ontology and pathway enrichment also reveal differential expression of renin-angiotensin system genes in the KEGG pathway in the left atrial myocardium of MR pigs [7] . Moreover, some of the genes expressed differentially in the left atrial myocardium could be regulated by angiotensin II type I receptor blocker [7] . However, the key genes of the renin-angiotensin system that are expressed differentially in the left atrial myocardium of MR patients have never been explored. Therefore, the aim of this study was to determine what key genes of the renin-angiotensin system are expressed differentially in the left atrium in severe MR patients with HF compared to normal controls. Since the left atrium is smaller in aortic valve disease patients compared to MR patients, the left atrial myocardium specimens from severe aortic valve disease patients with HF were also used as a separate cohort for gene analyses. The information regarding renin-angiotensin system and the KEGG pathway was obtained online from GenomeNet Database Resources (https://www.genome.jp/kegg-bin/show_pathway?hsa04614). This study revealed that several key element genes of the renin-angiotensin system were differentially expressed in the left atrium in MR patients in comparison with aortic valve disease patients and normal controls. Notably, the differential expressions were independent of circulating angiotensin II levels.
Materials and Methods

Ethics Statement.
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Committee for Human Research of Chang Gung Memorial Hospital (102-2219C). Written informed consent was obtained from each study patient.
Patient
Population. This study enrolled 18 severe nonischemic MR patients with HF in sinus rhythm (age: 57 ± 11 years), 12 patients with severe degenerative aortic valve disease and HF in sinus rhythm (age: 60 ± 12 years; aortic stenosis in 5, aortic regurgitation in 5, combined aortic stenoregurgitation in 2), and 16 control subjects without valve disease and HF. Exclusion criteria included previous myocardial infarction, febrile disorder, infectious or inflammatory disease, autoimmune disease, malignancy, acute and/or chronic viral hepatitis, and current use of immunosuppressive drugs.
Eleven left atrial tissue samples from normal adults were purchased for use as normal controls. Of these, six tissue samples were used for gene studies (24-year-old Caucasian male, 27-year-old Caucasian male, 30-year-old Asian male, 60-year-old Caucasian female, 76-year-old Caucasian female, and 77-year-old Caucasian male; BioChain, Newark, CA, USA). Five tissue samples were used for measuring tissue angiotensin II and angiotensin 1~7 concentrations. Of these, one sample (35-year-old Caucasian female) was obtained from G-Biosciences (St Louis, MO, USA), and four samples (49-year-old African American male, 60-year-old Caucasian female, 62-year-old Caucasian female, and 77-year-old Caucasian male) were obtained from BioChain (Newark, CA, USA).
2.3. Specimen Storage. During surgery, small specimens of atrial tissue were collected from the left atrial free wall of patients with MR and aortic valve disease. Excised atrial tissues were immediately frozen in liquid nitrogen and stored at −80°C for subsequent analyses.
Blood samples collected from MR patients, aortic valve disease patients, and control subjects without valve disease and HF were stored in tubes containing EDTA. The blood samples were centrifuged at 3000 rpm for 10 minutes at 4°C, aliquoted into Eppendorf tubes, and stored at −80°C. Table 2 lists the clinical characteristics of the MR patients with HF, aortic valve disease patients with HF, and control subjects without valve disease and HF. The HF status did not significantly differ between MR patients with HF and aortic valve disease patients with HF. The MR patients and the aortic valve disease patients did not significantly differ in age (P = 0 396), prevalence of hypertension (P = 0 710), prevalence of diabetes mellitus (P = 0 632), use of β-blockers (P = 1 000), or use of calcium channel blockers (P = 0 461). Left atrial size was significantly larger in the MR patients with HF compared to the aortic valve disease patients with HF (P = 0 019). However, left ventricular size and ejection fraction did not significantly differ between MR patients with HF and aortic valve disease patients with HF.
Measurement of Plasma
Results
Baseline Characteristics of Study Population.
Comparison of Plasma Angiotensin II and Angiotensin 1~7 Concentrations among MR Patients with HF, Aortic
Valve Disease Patients with HF, and Control Subjects without Valve Disease and HF. Plasma angiotensin II concentrations did not significantly differ between MR patients and aortic valve disease patients (35.18 ± 9.03 vs. 30.13 ± 8.45 pg/mL, P = 0 582) (Figure 1(a) ). However, MR patients had significantly higher plasma angiotensin II concentrations compared to controls (35.18 ± 9.03 vs. 7.94 ± 1.79 pg/mL, P = 0 004). Aortic valve disease patients had higher plasma angiotensin II concentrations compared to controls, but the difference did not reach statistical significance (30.13 ± 8.45 vs. 7.94 ± 1.79 pg/mL, P = 0 063).
The MR patients had significantly higher plasma angiotensin 1~7 concentrations compared to aortic valve disease patients (2.42 ± 0.68 vs. 0.96 ± 0.16 ng/mL, P = 0 001) (Figure 1(b) ). The MR patients had significantly higher plasma angiotensin 1~7 concentrations compared to controls (2.42 ± 0.68 vs. 0.85 ± 0.12 ng/mL, P < 0 001). Plasma angiotensin 1~7 concentrations did not significantly differ between aortic valve disease patients and control subjects (0.96 ± 0.16 vs. 0.85 ± 0.12 ng/mL, P = 0 164). To determine the effects of MR and HF on the gene expression profiles of the renin-angiotensin system, gene expression profiles of the renin-angiotensin system in the left atrium were compared in left atrial tissues from MR patients with HF (n = 10), aortic valve disease patients with HF (n = 8), and normal controls (n = 6). Table 1 shows the 17 genes examined in this study, all of which are known to have important roles in the KEGG pathway of the renin-angiotensin system (https://www. genome.jp/kegg-bin/show_pathway?hsa04614). Table 3 shows that, compared to normal controls, the MR patients with HF had significantly downregulated expressions of angiotensin-converting enzyme (ACE) (fold change: 0.31, downregulation), angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 (ACE2) (fold change: 0.15, downregulation), angiotensin II receptor, type 1 (AT1) 
Gene Expression in
Gene name
Assay identification (Table 3 ). The MR patients with HF also had upregulated expression of aldosterone synthase (CYP11B2) in the left atrium, which was not detected in normal controls (Table 3) . Compared to normal controls, the aortic valve disease patients had significantly downregulated expressions of ACE (fold change: 0.21, downregulation), ACE2 (fold change: 0.03, downregulation), AT1 (fold change: 0.32, downregulation), ENPEP (fold change: 0.44, downregulation), THOP1 (fold change: 0.57, downregulation), NLN (fold change: 0.43, downregulation), ANPEP (fold change: 0.16, downregulation), CTSG (fold change: 0.37, downregulation), LNPEP (fold change: 0.57, downregulation), MME (fold change: 0.04, downregulation), and CPA3 (fold change: 0.16, downregulation) in the left atrium. In contrast, the aortic valve disease patients with HF had significantly upregulated expression of MAS1 (fold change: 292.81, upregulation) in the left atrium compared to normal controls (Table 3 ). Figure 1 shows that the MR patients with HF and the aortic valve disease patients with HF had similar plasma angiotensin II concentrations. However, Table 3 and with heart failure, in aortic valve disease (AVD) patients with heart failure, and in control subjects without valve disease or heart failure (NC). * P < 0 05.
shows that, compared to the aortic valve disease patients with HF, the MR patients with HF had significantly upregulated expression of MAS1 expression (fold change: 189.18, upregulation, P = 0 016 by univariate analysis ( Figure 2) ; P = 0 003 with adjustment for plasma angiotensin II concentration and P = 0 007 with adjustment for left atrial size by analysis of covariance) in the left atrium. Expression of renin and angiotensin II receptor type 2 in the left atrium was not detected in most MR patients with HF and in most aortic valve disease patients with HF. The MR patients with and without treatment with renin-angiotensin system blockers (n = 7 vs. n = 3) did not significantly differ in expressions of ACE (11.85 ± 0.53 vs. 13.07 ± 1.00, P = 0 305), ACE2 (11.81 ± 0.68 vs. 10.90 ± 2.57, P = 0 770), AT1 (13.58 ± 0.48 vs. 12.66 ± 0.30, P = 0 197), ENPEP (8.78 ± 0.18 vs. 9.02 ± 0.71, P = 0 606), AGT (5.20 ± 0.37 vs. 5.13 ± 0.48, P = 0 909), CTSA (6.44 ± 0.22 vs. 5.77 ± 0.65, P = 0 305), THOP1 (9.75 ± 0.53 vs. 8.81 ± 0.65, P = 0 210), ANPEP (10.97 ± 0.60 vs. 8.96 ± 0.31, P = 0 143), CTSG (12.01 ± 0.60 vs. 10.94 ± 0.57, P = 0 245), LNPEP (8.43 ± 0.65 vs. 6.70 ± 0.80, P = 0 138), MME (11.33 ± 0.67 vs. 10.23 ± 0.21, P = 0 380), CPA3 (11.89 ± 0.85 vs. 9.24 ± 0.92, P = 0 079), and MAS1 (6.74 ± 1.21 vs. 5.46 ± 1.12, P = 0 569). The MR patients (n = 12) had significantly lower tissue angiotensin II concentrations compared to control subjects (n = 5) without valve disease or HF (4.44 ± 1.04 vs. 9.60 ± 2.69 pg/mL, P = 0 023). Most of the MR patients in this study had received angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (Table 2) . Angiotensin II receptor blockers have been shown to reduce tissue angiotensin II concentrations in the atria [7] . Tissue angiotensin 1~7 concentrations did not significantly differ between MR patients (n = 11) and control subjects (n = 5) without valve disease and HF (2.13 ± 0.32 vs. 2.08 ± 0.59 ng/mL, P = 0 865).
Discussion
This study showed that gene expression patterns of the renin-angiotensin system in the left atrium in MR patients with HF differed from those in aortic valve disease patients with HF and normal controls. Notably, for three genes in the renin-angiotensin system (CTSA, LNPEP, and MAS1), the differences were statistically significant.
To date, the gene expression profiles of the reninangiotensin system in the atrial myocardium of MR patients have never been examined. A previous study using an atrial fibrillation pig model showed that atrial myocytes express all components of the renin-angiotensin system and undergo structural changes in response to rapid atrial pacing [8] . In another study, a canine model showed that an increased left ventricular mass was associated with increased ACE expression, increased chymase activity, and increased angiotensin II expression in the left ventricular myocardium [9] . In contrast, our study showed that ACE gene expression was decreased in the left atrial myocardium of MR patients when compared to normal controls. The different ACE expression in the left atrium and left ventricle in MR patients could be attributable to different hemodynamic stress on the left atrium and left ventricle. Renin-angiotensin system blockers might also have different effects on atrial and ventricular remodeling [10, 11] .
Cathepsins, which are lysosomal proteases known to degrade unwanted intracellular or endocytosed proteins, reportedly play functional roles in the pathogenesis of heart disease by contributing to matrix turnover, chamber dilation, and structural remodeling [12] . Cathepsins may also be useful biomarkers for cardiovascular disease and pharmacological targets to remedy the progression of cardiovascular disease [12] . To date, however, information regarding the role of cathepsin A (CTSA) in cardiovascular disease is still limited. In vitro cathepsin A rapidly inactivates endothelin-1. Cathepsin A also hydrolyzes angiotensin I, which transforms angiotensin I into angiotensin-(1-9) or converts it to angiotensin II [13, 14] . Both angiotensin II and endothelin- patients with heart failure (n = 10), in aortic valve disease patients (AVD) with heart failure (n = 8), and in purchased samples from normal subjects (NC) (n = 6). * P < 0 05.
1 have mitogenic effects on cardiac myocytes and play important roles in atrial structural remodeling in patients with structural heart disease and patients with atrial fibrillation [15, 16] . In the current study, cathepsin A expression in the left atrium was significantly downregulated in MR patients in comparison with aortic valve disease patients and normal controls. Therefore, increased tissue endothelin-1 levels in MR patients may contribute to atrial structural remodeling. Leucyl/cystinyl aminopeptidase (LNPEP) is a catalyst in the final step of conversion of angiotensinogen to angiotensin IV. Leucyl/cystinyl aminopeptidase also cleaves vasopressin, oxytocin, bradykinin, and other peptide hormones [17] . Leucyl/cystinyl aminopeptidase is reportedly linked to glucose transport and utilization and to cognitive function [18, 19] . Interestingly, our prior study showed increased glycogen accumulation in the atrial myocytes of MR patients [5] . The MR patients in the current study showed significant downregulation of leucyl/cystinyl aminopeptidase expression in the left atrium in comparison with aortic valve disease patients and normal controls. Mice deficient in leucyl/ cystinyl aminopeptidase reportedly have an increased heart size [20] . However, additional information regarding the role of leucyl/cystinyl aminopeptidase in human cardiovascular disease is limited.
The MAS1 oncogene, a G-protein-coupled receptor and an endogenous receptor for the angiotensin-(1-7), can hetero-oligomerize with the AT1 receptor. By doing so, MAS1 oncogene acts as a physiological antagonist to the AT1 receptor and activates the antiproliferative, antifibrotic, and antithrombotic effects of angiotensin-(1-7) [21, 22] . In the current study, MAS1 expression in the left atrium was significantly upregulated in the MR patients in comparison with aortic valve disease patients and normal controls. In contrast, expression of AT1 receptor in the left atrium was significantly downregulated in the MR patients in comparison with normal controls. However, tissue angiotensin 1~7 concentrations did not significantly differ between MR patients and control subjects without valve disease and HF. The cardiac expression of MAS reportedly responds to various pathological stimuli, which suggests that MAS may be involved in homeostasis of the heart as well as the establishment and progression of cardiac disease [23] .
Taken together, the data obtained in this study indicate that expressions of CTSA, LNPEP, and MAS1 in the reninangiotensin system in the left atrial myocardium of MR patients substantially differed from those in aortic valve disease patients, even after adjustment for plasma angiotensin II concentration and left atrial size. These differential gene expressions result from the biological response to the volume overload induced by MR and might have implications for atrial structural remodeling (hypertrophy, myolysis, dedifferentiation, apoptosis, and fibrosis) [4, 5, 7, 24] and atrial enlargement in MR patients.
Study Limitations.
This study has several limitations. First, although significant differences were observed among the groups in this study, the number of subjects was relatively small. Therefore, studies with larger sample sizes are warranted. Second, most of the MR patients enrolled in the study had received renin-angiotensin system blockers, which may have modified the expressions of some genes. Notably, however, expressions of the 13 genes of the reninangiotensin system did not significantly differ between MR patients treated with and without renin-angiotensin system blockers. Finally, this study did not specifically investigate the functional and regulatory roles of CTSA, LNPEP, and MAS1 in atrial structural remodeling in MR patients.
Conclusions
Expressions of genes in the renin-angiotensin system, especially CTSA, LNPEP, and MAS1, in the left atrium in MR patients significantly differed from those in aortic valve disease patients and normal controls, and the differences were independent of circulating angiotensin II levels. The results of this study can provide a rationale for pharmacological therapies or posttranslational regulation therapies targeting differentially expressed genes in the renin-angiotensin system to remedy the structural remodeling associated with atrial enlargement and the progression of HF in patients with MR.
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